Quarterly report [Sections 13 or 15(d)]

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)						3 Months Ended
	Nov. 18, 2024	May 20, 2024	May 13, 2024	Mar. 26, 2021	Jul. 18, 2016	Mar. 31, 2025	Mar. 31, 2024	May 12, 2025	Feb. 26, 2025	Dec. 31, 2024	Nov. 21, 2024	Jun. 30, 2024	Apr. 25, 2024	Dec. 31, 2023	Aug. 24, 2022
Loss Contingencies [Line Items]
Exercise price									$ 2.8375
Fair value						$ (126,000)	$ (658,000)
Stock issued during period, value, issued for services						340,000
Research and development expense						1,099,000	777,000
Contigency minimum required											$ 2,500,000
Equity, Attributable to Parent						(980,000)	5,312,000			$ (1,670,000)				$ 7,476,000
Minimum [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Equity, Attributable to Parent								$ 2,500,000
2023 Sponsored Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense		$ 1,700,000
Research and development expense						216,000	0
Unbilled and unaccrued amounts						431,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Proceeds from upfront amount			$ 145,000		$ 200,000
License maintenance fees			$ 100,000		$ 100,000
Royalty fee percentage			6.00%		4.00%
Performance milestone payments			$ 3,100,000		$ 3,100,000
One-time sales milestone payments			1,000,000		1,000,000
Gross sales			250,000,000		250,000,000
Sales revenue			5,000,000		5,000,000
Cumulative gross sales			500,000,000		$ 500,000,000
Royalty expense year one			250,000
Royalty expense years two through five			2,000,000
Royalty expense year six and thereafter			$ 5,000,000
2016 Patent Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage			5.00%		6.00%
2016 Patent Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage			1.00%
2016 Patent Exclusive License Agreement [Member] \| 2017 through 2020 [Member]
Loss Contingencies [Line Items]
License maintenance fees					$ 200,000
2016 Patent Exclusive License Agreement [Member] \| Beginning in 2022 [Member]
Loss Contingencies [Line Items]
Annual royalty payments					250,000
2016 Patent Exclusive License Agreement [Member] \| Beginning in 2025 [Member]
Loss Contingencies [Line Items]
License maintenance fees			$ 50,000
Annual royalty payments					2,000,000
2016 Patent Exclusive License Agreement [Member] \| Beginning in 2027 [Member]
Loss Contingencies [Line Items]
Annual royalty payments					$ 5,000,000
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
License maintenance fees				$ 5,000
Performance milestone payments				3,100,000
One-time sales milestone payments				1,000,000
Gross sales				250,000,000
Sales revenue				5,000,000
Cumulative gross sales				500,000,000
Upfront license fee				20,000
Royalty expense year one though four				250,000
Royalty expense year five and thereafter				$ 2,000,000
2021 Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage				5.00%
2021 Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage				2.50%
2024 GTB-3650 Clinical Trial Agreement [Member]
Loss Contingencies [Line Items]
Unbilled and unaccrued amounts						1,900,000
Annual royalty payments	$ 2,000,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Research and development expenses						532,000	269,000
Cash payments						$ 268,000	1,800,000
Issuance of pre-funded warrants						326,251
Exercise price						$ 0.0001
Fair value						$ 847,000
Cytovance Biologics Inc [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Research and development expenses						$ 532,000	$ 269,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage												5.00%	9.90%		4.90%